Resources Repository
-
ArticlePublication 2023Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual …
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual in 2022, merging processes from all 4 Health Technology Evaluation programs into a single document. Key changes include introducing a new disease severity modifier while maintaining existing methods on health inequality, discounting, unrelated healthcare costs, and value of information. Changes were categorized by importance, with most being modest updates or clarifications aligning with existing principles. The methods involved a 2-stage…
Technology Assessment | Europe | Health/Medicine -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Decision Theory | Middle East & North Africa | Costing Methods | Health Outcomes | State-Transition | Decision Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Value of Information | Europe | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | North America